share_log

Chardan Capital Maintains Buy on Pear Therapeutics, Lowers Price Target to $9

Chardan Capital Maintains Buy on Pear Therapeutics, Lowers Price Target to $9

查丹资本维持对Pear Therapeutics的买入,将目标股价下调至9美元
Benzinga Real-time News ·  2022/08/12 09:04

Chardan Capital analyst Keay Nakae maintains Pear Therapeutics (NASDAQ:PEAR) with a Buy and lowers the price target from $13 to $9.

Chardan Capital分析师Keay Nakae维持Pear Therapeutics(纳斯达克股票代码:PEAR)的买入,并将目标股价从13美元下调至9美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发